Wealth Management Nebraska Trims Stock Holdings in Axon Enterprise, Inc $AXON

Wealth Management Nebraska decreased its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 6.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,933 shares of the biotechnology company’s stock after selling 144 shares during the period. Axon Enterprise accounts for about 0.2% of Wealth Management Nebraska’s portfolio, making the stock its 27th biggest holding. Wealth Management Nebraska’s holdings in Axon Enterprise were worth $1,582,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. TCTC Holdings LLC boosted its stake in shares of Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 24 shares during the period. Bartlett & CO. Wealth Management LLC boosted its stake in shares of Axon Enterprise by 132.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 33 shares during the period. Banque Transatlantique SA bought a new position in shares of Axon Enterprise in the first quarter worth about $31,000. Catalyst Capital Advisors LLC bought a new position in shares of Axon Enterprise in the first quarter worth about $32,000. Finally, Flaharty Asset Management LLC bought a new position in shares of Axon Enterprise in the first quarter worth about $33,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Up 0.8%

Shares of AXON stock opened at $721.59 on Tuesday. Axon Enterprise, Inc has a 1 year low of $416.88 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. The stock’s 50 day simple moving average is $757.50 and its two-hundred day simple moving average is $710.51. The company has a market cap of $56.65 billion, a PE ratio of 178.17, a price-to-earnings-growth ratio of 27.79 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. During the same period in the prior year, the business posted $1.20 earnings per share. The company’s quarterly revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. Research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Transactions at Axon Enterprise

In other news, Director Jeri Williams sold 100 shares of the stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total value of $75,254.00. Following the sale, the director directly owned 1,416 shares in the company, valued at approximately $1,065,596.64. This represents a 6.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Jennifer H. Mak sold 77 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $760.00, for a total value of $58,520.00. Following the completion of the sale, the chief accounting officer owned 15,003 shares in the company, valued at approximately $11,402,280. The trade was a 0.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 49,932 shares of company stock valued at $37,978,216. Company insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Morgan Stanley set a $885.00 price objective on Axon Enterprise and gave the stock an “overweight” rating in a research note on Friday, July 11th. Wolfe Research started coverage on Axon Enterprise in a research note on Monday, July 7th. They set an “outperform” rating for the company. JPMorgan Chase & Co. increased their price target on Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a research note on Thursday, July 17th. Craig Hallum raised Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price target for the company in a research note on Tuesday, August 5th. Finally, Bank of America increased their price target on Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $841.64.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.